Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. Hendriks LEL, Remon J, Reck M. J Thorac Oncol 2022;17:499-502.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hendriks LEL, Remon J, Reck M. Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. J Thorac Oncol 2022;17:499-502.
PMID: 35307106